Namour, F., Vanhoutte, F. P., Beetens, J., Blockhuys, S., Weer, M. D., & Wigerinck, P. (2012). Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects. Springer International Publishing.

Namour, Florence, Frédéric P. Vanhoutte, Johan Beetens, Stan Blockhuys, Marc De Weer, and Piet Wigerinck. Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given As Single and Multiple Doses to Healthy Male Subjects. Springer International Publishing, 2012.

Namour, Florence, et al. Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given As Single and Multiple Doses to Healthy Male Subjects. Springer International Publishing, 2012.